Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
& -
Welcome back everyone to the Fourth Annual H.C. Wainwright HBV Conference. My name is Patrick Trucchio. I'm the senior healthcare analyst at H.C. Wainwright. It's my pleasure to introduce our next speakers, Scot Roberts, CSO; and Scott Harris, CMO of Altimmune, a clinical-stage biopharmaceutical company focused on development of novel peptide-based therapeutics for treatment of obesity and liver diseases.
So first, perhaps we can start with Altimmune's synthetic peptide technology platform. How did it come to be in its current form, and what makes it differentiated from others in the market?
Questions & Answers
Sure. I can handle that, Patrick, and thank you for inviting us to talk about HepTcell today. So our peptide technology that we're using for HepTcell is based on an approach for maintaining the persistence of the peptides. This is a peptide-based product meant to stimulate T cells against the HBV virus and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |